Transcriptional evidence of reduced BDNF trophic capacity in the post-mortem human midbrain of schizophrenia cases with high inflammation.

IF 5.8 1区 医学 Q1 PSYCHIATRY
Jessica J Chandra, Yunting Zhu, Alice Petty, Yasmine Kostoglou, William X Haynes, Maree J Webster, Cynthia S Weickert
{"title":"Transcriptional evidence of reduced BDNF trophic capacity in the post-mortem human midbrain of schizophrenia cases with high inflammation.","authors":"Jessica J Chandra, Yunting Zhu, Alice Petty, Yasmine Kostoglou, William X Haynes, Maree J Webster, Cynthia S Weickert","doi":"10.1038/s41398-025-03359-7","DOIUrl":null,"url":null,"abstract":"<p><p>Elevated inflammation in the midbrain of ~45% of people with schizophrenia may relate to altered trophic support for neurons. Dopamine neurons require trophic support from Brain-Derived Neurotrophic Factor (BDNF), that signals via the full-length Tropomyosin kinase B receptor (TrkB<sup>TK+</sup>). The truncated BDNF receptor (TrkB<sup>TK-</sup>) and the apoptosis-related p75 receptor may counteract the effects of BDNF. We hypothesised that transcriptional changes in either BDNF, and/or a transcription factor critical for the maintenance of dopamine neurons (Nuclear Receptor Related-1 protein; NURR1), and/or BDNF receptors - TrkB (TK+ or TK-) and p75, would be found in the post-mortem schizophrenia midbrain, particularly in schizophrenia cases defined as \"high inflammation\". The neuroinflammatory status was delineated based on elevated expression levels of a combination of pro-inflammatory transcripts (SERPINA3, IL6, IL1β and TNFα) and defined as a subgroup (46%) by 2-step recursive clustering. Using RT-qPCR, mRNA levels of NURR1, BDNF, TrkB and p75 was quantified in schizophrenia (n = 65) and control (n = 64) ventral mesencephalon. We found significant decreases in BDNF, TrkB<sup>TK+</sup> and NURR1 (14-18%) and increases in TrkB<sup>TK-</sup> and p75 (18-35%) mRNA levels in schizophrenia compared to controls (all p < 0.05), with exacerbation of changes identified in high inflammation schizophrenia. To determine whether these changes would be consistent with resulting from chronic antipsychotic treatment, we treated healthy adult rats with antipsychotics (haloperidol and risperidone) for 7 months and found all transcripts to be unaltered compared to control rats. SnRNAseq of human midbrain showed that p75 receptor mRNA is primarily localised in oligodendrocytes and pan-TrkB mRNA is in both neurons and astrocytes. We confirmed that p75 was localised to oligodendrocyte-like cells by immunohistochemistry. Altogether, we find transcriptional evidence of reduced trophic support in schizophrenia midbrain and suggest that this may directly impact dopamine neuron health, particularly when neuroinflammation is also present.</p>","PeriodicalId":23278,"journal":{"name":"Translational Psychiatry","volume":"15 1","pages":"162"},"PeriodicalIF":5.8000,"publicationDate":"2025-05-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12059047/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Translational Psychiatry","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1038/s41398-025-03359-7","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"PSYCHIATRY","Score":null,"Total":0}
引用次数: 0

Abstract

Elevated inflammation in the midbrain of ~45% of people with schizophrenia may relate to altered trophic support for neurons. Dopamine neurons require trophic support from Brain-Derived Neurotrophic Factor (BDNF), that signals via the full-length Tropomyosin kinase B receptor (TrkBTK+). The truncated BDNF receptor (TrkBTK-) and the apoptosis-related p75 receptor may counteract the effects of BDNF. We hypothesised that transcriptional changes in either BDNF, and/or a transcription factor critical for the maintenance of dopamine neurons (Nuclear Receptor Related-1 protein; NURR1), and/or BDNF receptors - TrkB (TK+ or TK-) and p75, would be found in the post-mortem schizophrenia midbrain, particularly in schizophrenia cases defined as "high inflammation". The neuroinflammatory status was delineated based on elevated expression levels of a combination of pro-inflammatory transcripts (SERPINA3, IL6, IL1β and TNFα) and defined as a subgroup (46%) by 2-step recursive clustering. Using RT-qPCR, mRNA levels of NURR1, BDNF, TrkB and p75 was quantified in schizophrenia (n = 65) and control (n = 64) ventral mesencephalon. We found significant decreases in BDNF, TrkBTK+ and NURR1 (14-18%) and increases in TrkBTK- and p75 (18-35%) mRNA levels in schizophrenia compared to controls (all p < 0.05), with exacerbation of changes identified in high inflammation schizophrenia. To determine whether these changes would be consistent with resulting from chronic antipsychotic treatment, we treated healthy adult rats with antipsychotics (haloperidol and risperidone) for 7 months and found all transcripts to be unaltered compared to control rats. SnRNAseq of human midbrain showed that p75 receptor mRNA is primarily localised in oligodendrocytes and pan-TrkB mRNA is in both neurons and astrocytes. We confirmed that p75 was localised to oligodendrocyte-like cells by immunohistochemistry. Altogether, we find transcriptional evidence of reduced trophic support in schizophrenia midbrain and suggest that this may directly impact dopamine neuron health, particularly when neuroinflammation is also present.

高炎症精神分裂症患者死后中脑BDNF营养能力降低的转录证据
约45%的精神分裂症患者中脑炎症升高可能与神经元营养支持改变有关。多巴胺神经元需要脑源性神经营养因子(BDNF)的营养支持,该信号通过全长原肌球蛋白激酶B受体(TrkBTK+)发出。截断的BDNF受体(TrkBTK-)和凋亡相关的p75受体可能抵消BDNF的作用。我们假设BDNF和/或对维持多巴胺神经元至关重要的转录因子的转录变化(核受体相关-1蛋白;NURR1)和/或BDNF受体- TrkB (TK+或TK-)和p75,将在死后精神分裂症中脑中发现,特别是在被定义为“高炎症”的精神分裂症病例中。根据促炎转录物(SERPINA3、IL6、IL1β和TNFα)组合的表达水平升高来描述神经炎症状态,并通过两步递归聚类将其定义为一个亚组(46%)。采用RT-qPCR方法,对精神分裂症(n = 65)和对照组(n = 64)中脑腹侧NURR1、BDNF、TrkB和p75 mRNA水平进行定量分析。我们发现,与对照组相比,精神分裂症患者BDNF、TrkBTK+和NURR1显著降低(14-18%),TrkBTK-和p75 mRNA水平显著升高(18-35%)
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
CiteScore
11.50
自引率
2.90%
发文量
484
审稿时长
23 weeks
期刊介绍: Psychiatry has suffered tremendously by the limited translational pipeline. Nobel laureate Julius Axelrod''s discovery in 1961 of monoamine reuptake by pre-synaptic neurons still forms the basis of contemporary antidepressant treatment. There is a grievous gap between the explosion of knowledge in neuroscience and conceptually novel treatments for our patients. Translational Psychiatry bridges this gap by fostering and highlighting the pathway from discovery to clinical applications, healthcare and global health. We view translation broadly as the full spectrum of work that marks the pathway from discovery to global health, inclusive. The steps of translation that are within the scope of Translational Psychiatry include (i) fundamental discovery, (ii) bench to bedside, (iii) bedside to clinical applications (clinical trials), (iv) translation to policy and health care guidelines, (v) assessment of health policy and usage, and (vi) global health. All areas of medical research, including — but not restricted to — molecular biology, genetics, pharmacology, imaging and epidemiology are welcome as they contribute to enhance the field of translational psychiatry.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信